Cartesian Therapeutics ( (RNAC) ) has provided an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Cartesian Therapeutics announced promising results from its Phase 2b trial of Descartes-08, an mRNA cell therapy for myasthenia gravis (MG), showcasing deep, durable responses without preconditioning chemotherapy. The company plans to start a Phase 3 AURORA trial in 2025, focusing on the improvement of daily living activities in MG patients. The therapy was well-tolerated in outpatient settings, with no severe adverse effects, highlighting its potential as a significant treatment advancement for MG.
For detailed information about RNAC stock, go to TipRanks’ Stock Analysis page.
